N@N

Ligand Pharmaceuticals Inc (NASDAQ:LGND), Up By 27.65% ($3.28) From $11.870 After BUYINS.NET Report Predicted Strength Before E

^{Published on 2012-02-10 07:40:56 - WOPRAI}
 

February 10, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, January 2nd 2012 stating that Ligand Pharmaceuticals Inc (NASDAQ:LGND) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=lgnd&id=226783

At the time this story was written, Ligand Pharmaceuticals Inc (NASDAQ:LGND) is Up By 27.65% ($3.28) From $11.870 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Ligand Pharmaceuticals Inc (NASDAQ:LGND) - Ligand Pharmaceuticals Incorporated operates as a biotechnology company. It principally engages in the development and acquisition of royalty revenue generating assets. The company engages in the research, milestone, and royalty revenue activities resulting from its collaborations with pharmaceutical partners. The collaborations primarily include ongoing clinical programs at Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Merck & Co., Cephalon, Inc, and Celgene. These partnered product candidates are being studied for the treatment of indications, such as thrombocytopenia, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, osteoporosis, menopausal symptoms, and Alzheimers disease. Ligand Pharmaceuticals Incorporated receives royalties principally on sales of Avinza from Pfizer, Promacta from GlaxoSmithKline, and Viviant /Conbriza from Pfizer. The company through its subsidiary, CyDex Pharmaceuticals, Inc., offers four marketed products, as well as has one approved product, a portfolio of partnered drug development programs, an internal pipeline of proprietary drugs, and the Captisol drug formulation platform technology. Ligand Pharmaceuticals Incorporated was formerly known as Progenx Inc. and changed its name in 1989. The company was founded in 1987 and is based in La Jolla, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Ligand Pharmaceuticals Inc (NASDAQ:LGND) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net